Pharmacy

Drugmakers have pushed back their resupply estimates for carboplatin, one of four chemotherapy drugs in a monthslong shortage, with some formulations now not expected to return until 2027. Cisplatin, carboplatin, oxaliplatin and ifosfamide, which form the backbone of treatment for…

The Health Resources and Services Administration has revised its 340B Rebate Model Pilot Program, establishing a voluntary pathway for qualifying drug manufacturers to provide 340B ceiling prices through rebates rather than upfront discounts for a limited group of covered outpatient…

Volatility in global oil markets could significantly increase the cost of manufacturing essential medicines and expose vulnerabilities in pharmaceutical supply chains, according to a July Unitaid report. Here are five things to know:

Polypharmacy was the only higher-risk medication exposure independently associated with increased all-cause mortality among older adults after accounting for drug-drug interactions and potentially inappropriate medications, according to a study published in the Journal of the American Geriatrics Society. Here are…

The University of Kansas School of Pharmacy’s Doctor of Pharmacy program has been placed on “accredited with probation” status by the Accreditation Council for Pharmacy Education after the accreditor identified deficiencies in experiential learning, student services, faculty staffing, governance and…

Houston, Mo.-based Texas County Memorial Hospital will close its Hutcheson Pharmacy on Aug. 21 after evaluating its retail pharmacy operations, according to a July 31 Ozark Radio News report. Hospital leaders cited recent manufacturing restrictions affecting retail pharmacy operations, ongoing…

Houston-based Memorial Hermann Health System has opened its fifth retail pharmacy, with four more planned across the system within the next year, Binita Patel, PharmD, vice president of pharmacy services, told Becker’s. The latest addition is a second location at…

The 340B Drug Pricing Program has faced mounting legal pressure throughout 2026, including Eli Lilly’s enforcement of a claims-data requirement that has left roughly 1,000 noncompliant covered entities exposed to suspended 340B pricing, and CVS’s motions to dismiss lawsuits from…

An FDA advisory committee voted 9-3 against Capricor Therapeutics’ cell therapy deramiocel for Duchenne muscular dystrophy-associated cardiomyopathy after concluding the available evidence did not demonstrate the therapy’s effectiveness. The vote followed FDA briefing documents released ahead of the meeting that…

The National Association of Boards of Pharmacy is developing a national adverse event reporting clearinghouse for compounded medications that will collect reports of patient harm and share them among state boards of pharmacy and the FDA. The organization said the…